Caplacizumab for congenital thrombotic thrombocytopenic purpura

Aaron Boothby, Marshall Mazepa

Research output: Contribution to journalLetterpeer-review

1 Scopus citations

Abstract

Caplacizumab rapidly increased platelet count which likely shorted the hospital stay and reduced plasma transfusion requirement.

Original languageEnglish (US)
Pages (from-to)E420-E421
JournalAmerican Journal of Hematology
Volume97
Issue number11
DOIs
StatePublished - Nov 2022

Keywords

  • ADAMTS13 Protein
  • Blood Component Transfusion
  • Humans
  • Plasma
  • Plasma Exchange
  • Purpura, Thrombotic Thrombocytopenic/drug therapy
  • Single-Domain Antibodies
  • von Willebrand Factor

PubMed: MeSH publication types

  • Letter

Fingerprint

Dive into the research topics of 'Caplacizumab for congenital thrombotic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this